Filter By Category
Archives
Share on -
CETRORELIX
Generic Name: CETRORELIX
ABSTRACT -
Cetrorelix (Cetrotide) is a synthetic decapeptide antagonist of gonadotropin-releasing hormone (GnRH) receptors approved for the prevention of premature luteinising hormone (LH) surges in women undergoing controlled ovarian stimulation (COS) for assisted reproductive techniques (ART). By competitively blocking GnRH receptors in the pituitary, it immediately suppresses LH and FSH secretion without an initial flare effect, preventing premature ovulation. It is administered subcutaneously during COS cycles.
DOSAGE -
0.25 mg SC once daily starting on day 5 or 6 of ovarian stimulation and continued until hCG trigger day; or single 3 mg SC dose on day 7 of stimulation (sufficient for 96 hours of LH suppression).
SIDE EFFECTS -
- Injection site reactions (erythema, pruritus, bruising)
- Nausea
- Headache
- Ovarian hyperstimulation syndrome (OHSS) — related to COS protocol
- Abdominal discomfort
ALLERGIC REACTIONS -
These symptoms may indicate an allergic reaction and require immediate medical attention.
- Hypersensitivity including anaphylaxis
- Urticaria
- Angioedema
- Severe injection site hypersensitivity
DRUG INTERACTIONS-
- No significant pharmacokinetic drug interactions identified
- Ovarian stimulation agents (gonadotropins): no PK interaction; clinical coordination required
- Drugs prolonging QT interval: theoretical caution
PREAUTONS–
- OHSS risk is due to gonadotropin stimulation, not cetrorelix itself — monitor follicle development
- Pregnancy: discontinue immediately if pregnancy detected during cycle
- Renal impairment: mild-moderate acceptable; severe renal impairment — no data
- Latex allergy: pre-filled syringe tip cap contains latex
WARNINGS –
- Anaphylactic reactions reported — first dose should be administered under medical supervision
- Not for use during confirmed pregnancy
- OHSS can be life-threatening — withhold hCG trigger if ovarian response is excessive
Share on -
. Developed by